Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.39% |
| 2 | Financials | 6.67% |
| 3 | Healthcare | 6.18% |
| 4 | Industrials | 4.97% |
| 5 | Consumer Discretionary | 4.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BMTC
3451
DELISTED
Bryn Mawr Bank Corp
BMTC
| $2.86M | ﹤0.01% |
62,163
+35,845
| +136% | +$1.45M |
|
|
ACAHU
3452
DELISTED
Atlantic Coastal Acquisition Corp. Unit
ACAHU
| $2.86M | ﹤0.01% |
288,755
-185,739
| -39% | -$1.85M |
|
3453
Douglas Dynamics
PLOW
$916M
| $2.85M | ﹤0.01% |
78,560
-6,807
| -8% | -$262K |
|
3454
LCNB Corp
LCNB
$284M
| $2.85M | ﹤0.01% |
161,637
-92,650
| -36% | -$1.58M |
|
3455
Corvus Pharmaceuticals
CRVS
$1.13B
| $2.85M | ﹤0.01% |
588,272
+456,837
| +348% | +$1.35M |
|
|
EFOR
3456
Everforth Inc
EFOR
$1.25B
| $2.85M | ﹤0.01% |
25,156
-37,415
| -60% | -$3.94M |
|
|
BRFS
3457
DELISTED
BRF SA
BRFS
| $2.84M | ﹤0.01% |
566,100
+305,225
| +117% | +$1.44M |
|
3458
ABM Industries
ABM
$2.85B
| $2.84M | ﹤0.01% |
63,091
-546,991
| -90% | -$25.3M |
|
3459
CALL
Johnson Controls International
JCI
$88.8B
| $2.84M | ﹤0.01% |
+41,700
| New | +$3.01M |
|
3460
CALL
Medpace
MEDP
$16B
| $2.84M | ﹤0.01% |
+15,000
| New | +$2.74M |
|
|
HHLA.U
3461
DELISTED
HH&L Acquisition Co. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant
HHLA.U
| $2.84M | ﹤0.01% |
285,895
-934,005
| -77% | -$9.34M |
|
|
RCHG
3462
DELISTED
Recharge Acquisition Corp. Class A Common Stock
RCHG
| $2.84M | ﹤0.01% |
286,660
+250,000
| +682% | +$2.46M |
|
3463
Broadridge
BR
$18.2B
| $2.84M | ﹤0.01% |
17,027
+695
| +4% | +$118K |
|
3464
Maximus
MMS
$3.24B
| $2.83M | ﹤0.01% |
34,067
-21,419
| -39% | -$1.83M |
|
3465
Minerals Technologies
MTX
$2.28B
| $2.83M | ﹤0.01% |
40,559
+7,317
| +22% | +$559K |
|
3466
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.83M | ﹤0.01% |
216,924
+60,108
| +38% | +$918K |
|
|
ORIAU
3467
DELISTED
Orion Biotech Opportunities Corp. Units
ORIAU
| $2.83M | ﹤0.01% |
286,053
-163,647
| -36% | -$1.63M |
|
3468
ProQR Therapeutics
PRQR
$243M
| $2.83M | ﹤0.01% |
337,504
+325,364
| +2,680% | +$2.13M |
|
|
DCH
3469
Dauch Corp
DCH
$1.38B
| $2.82M | ﹤0.01% |
320,064
-389,216
| -55% | -$3.57M |
|
3470
Amcor
AMCR
$21B
| $2.82M | ﹤0.01% |
48,610
-258,196
| -84% | -$15.4M |
|
3471
H.B. Fuller
FUL
$3.03B
| $2.82M | ﹤0.01% |
43,635
+18,852
| +76% | +$1.22M |
|
3472
Fulcrum Therapeutics
FULC
$278M
| $2.81M | ﹤0.01% |
99,707
-525,928
| -84% | -$9.97M |
|
3473
Ocular Therapeutix
OCUL
$1.82B
| $2.81M | ﹤0.01% |
281,279
+266,135
| +1,757% | +$2.99M |
|
3474
Advanced Energy
AEIS
$11.6B
| $2.81M | ﹤0.01% |
32,030
+10,349
| +48% | +$968K |
|
3475
PUT
Transocean
RIG
$5.74B
| $2.81M | ﹤0.01% |
741,800
-400
| -0.1% | -$1.46K |
|
Similar funds
Millennium Management's Q3 2021 Portfolio in Review
As of Q3 2021, Millennium Management held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Millennium Management deployed $8.65B of net new capital in Q3 2021, opening 1,244 new positions and adding to 2,720 existing holdings. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M.
By sector, the portfolio is most concentrated in Technology at 7.4% of assets, down from 7.8% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $694M trimmed.
- Millennium Management's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Millennium Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Millennium Management's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Millennium Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Millennium Management's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Millennium Management opened 1,244 new positions and closed 981 in Q3 2021.
- Millennium Management's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.